LCAR-C18S

LCAR-C18S is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting Claudin 18.2 (CLDN18.2), a tight junction protein frequently overexpressed in various malignant solid tumors, particularly gastric and pancreatic cancers. Developed by Legend Biotech in collaboration with Shanghai East Hospital, the therapy involves the genetic modification of a patient's own T cells to express a CAR specific to CLDN18.2. Upon re-infusion, these modified T cells recognize and bind to CLDN18.2-positive tumor cells, triggering T-cell activation and subsequent tumor cell lysis. A Phase 1 clinical trial (NCT04467853) was conducted to evaluate the safety and efficacy of LCAR-C18S in patients with advanced solid tumors, though the study was ultimately terminated by the sponsors.

Other names

Autologous anti-Claudin18.2 CAR T cells